"This could be a tipping point, of sorts, in the history of this disease. The US hosts the most active COVID-19 cases of any country in the world, so if new cases are being dominated by this variant, I think it is a good bet that B.1.1.7 will eventually become the globally dominant variant if it is not already."
What about P.1 and B.1.351? Are they less contagious than B.1.1.7 to such an extent that they will be outcompeted?
I do not blame you for not taking Cuomo at this word. Unfortunately, his is not the only state government making such claims. Here are links to the official vaccination pages of New Jersey, California and Texas (I picked these three as New Jersey is next to New York, and California and Texas have large populations - not a very scientific approach, admittedly):
Whether these states are suffering from a lack of supply or a lack of distribution capacity, it seems clear that there is a serious issue related to getting vaccines into arms that has nothing to do with how many people are eligible.
I am puzzled by the focus on increasing the portion of the population that is eligible to be vaccinated. What does adjusting eligibility affect, on a practical level? Shouldn't the focus be on the availability of doses and the effectiveness of distribution?
"This could be a tipping point, of sorts, in the history of this disease. The US hosts the most active COVID-19 cases of any country in the world, so if new cases are being dominated by this variant, I think it is a good bet that B.1.1.7 will eventually become the globally dominant variant if it is not already."
What about P.1 and B.1.351? Are they less contagious than B.1.1.7 to such an extent that they will be outcompeted?
I do not blame you for not taking Cuomo at this word. Unfortunately, his is not the only state government making such claims. Here are links to the official vaccination pages of New Jersey, California and Texas (I picked these three as New Jersey is next to New York, and California and Texas have large populations - not a very scientific approach, admittedly):
https://covid19.nj.gov/pages/finder
https://myturn.ca.gov/
https://dshs.texas.gov/coronavirus/immunize/vaccine-hubs.aspx
Whether these states are suffering from a lack of supply or a lack of distribution capacity, it seems clear that there is a serious issue related to getting vaccines into arms that has nothing to do with how many people are eligible.
I am puzzled by the focus on increasing the portion of the population that is eligible to be vaccinated. What does adjusting eligibility affect, on a practical level? Shouldn't the focus be on the availability of doses and the effectiveness of distribution?